News

During this study, 41 out of the 43 patients treated showed a positive response to treatment. Serenity has also completed an end-of-Phase-II meeting with the FDA. John Sedor,

The BD Soluvia microinjection system offers a reliable method of intradermal delivery, which integrates a 1.5mm length BD microneedle with a 0.1ml injected volume. As a prefillable delivery

Prior to joining Illumina, Mr Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company’s initial public offering in 1993. Mr

According to Genzyme, Synvisc-One is the only single-injection viscosupplement approved for the treatment of osteoarthritis knee pain in the US. It is also approved in the EU and

Cypress said that the acquisition is consistent with its strategy of providing innovative products and services that address unmet medical needs in the fields of rheumatology and pain.

The funding will advance the company’s lead program targeted against NS4B, a specific region in the hepatitis C virus protein. David Cory, president and CEO of Eiger, said:

Mr Montague, who was CEO and a director of Mark IV Industries, retired in July 2009. Mark IV is a diversified global manufacturer of highly-engineered systems and components

According to the company, the Quill SRS Polydioxanone (PDO) is a longer-lasting absorbable suture, which is typically used for deeper tissue closures while Quill SRS Monoderm is made

This study is designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against TNF-alpha,